WHITE PLAINS, N.Y.--(BUSINESS WIRE)--Orgenesis Inc. (OTCBB:ORGS) (“Orgenesis” or the “Company”), a development-stage company with a novel therapeutic technology dedicated to converting a patient’s own liver cells into functioning insulin-producing cells as a treatment for diabetes, announced today that it has recently met with U.S. Food and Drug Administration’s (“FDA”) Center for Biologics Evaluation and Research (“CBER”) experts, briefing them on the scientific progress the Company has made to-date within the field of transdifferentiation and the promise those advancements may hold for the treatment of diabetes.
